In conflict with the above mentioned studies reporting adverse effects of serum chemerin, the metaanalysis of DNA microarray data demonstrated tumor expression of CMKLR1 and CCRL2 to exert significant beneficial effects on the OS of NSCLC patients, a fact that was supported for CMKLR1 by SNP analyses. This evidence concerns the gene RARRES2 and non-small cell lung carcinoma.